Technical Analysis for DMAC - DiaMedica Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
2.43 | -5.08% | -0.13 |
DMAC closed down 5.08 percent on Monday, August 19, 2019, on 48 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical DMAC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -5.08% | |
| Lower Bollinger Band Walk | Weakness | -5.08% | |
| Stochastic Reached Oversold | Weakness | -5.08% | |
| Wide Bands | Range Expansion | -5.08% | |
| Lower Bollinger Band Touch | Weakness | -5.08% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 07/18/2019
- Sector: Healthcare
- Industry: Biotechnology
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Kidney Diseases
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Kidney Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more DMAC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.53 |
| 52 Week Low | 0.2588 |
| Average Volume | 144,198 |
| 200-Day Moving Average | 3.338 |
| 50-Day Moving Average | 3.7895 |
| 20-Day Moving Average | 3.2715 |
| 10-Day Moving Average | 2.935 |
| Average True Range | 0.4034 |
| ADX | 28.24 |
| +DI | 9.7469 |
| -DI | 28.0492 |
| Chandelier Exit (Long, 3 ATRs ) | 2.7298 |
| Chandelier Exit (Short, 3 ATRs ) | 3.4202 |
| Upper Bollinger Band | 4.185 |
| Lower Bollinger Band | 2.358 |
| Percent B (%b) | 0.04 |
| BandWidth | 55.845942 |
| MACD Line | -0.3543 |
| MACD Signal Line | -0.2594 |
| MACD Histogram | -0.0949 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.88 | ||||
| Resistance 3 (R3) | 2.92 | 2.81 | 2.81 | ||
| Resistance 2 (R2) | 2.81 | 2.70 | 2.79 | 2.78 | |
| Resistance 1 (R1) | 2.62 | 2.62 | 2.57 | 2.58 | 2.75 |
| Pivot Point | 2.51 | 2.51 | 2.48 | 2.49 | 2.51 |
| Support 1 (S1) | 2.32 | 2.40 | 2.27 | 2.28 | 2.11 |
| Support 2 (S2) | 2.21 | 2.32 | 2.19 | 2.08 | |
| Support 3 (S3) | 2.02 | 2.21 | 2.06 | ||
| Support 4 (S4) | 1.98 |
